Serum and urinary cytokine levels of SLE patients

Pharmazie

Volumn 67, Issue 5, 2012, Pages 411-413

  Brugos, Boglarka ^a   Vincze, Z ^a   Sipka, S ^a   Szegedi, G ^a   Zeher, M ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; LABORATORY TEST; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PROTEIN BLOOD LEVEL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; BIOLOGICAL MARKERS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKINS; KIDNEY DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84862324329     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2012.1694     Document Type: Article

References (19)

1. Agrawal S (2004) Lupus nephritis: an update on pathogenesis. J Indian Rheumatol Assoc 12: 11-15.
2. Aringer M, Smolen J (2008) The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther 10: 1-8.
3. Cameron J (1999) Lupus nephritis. J Am Soc Nephrol 10: 413-424.
4. Chan R, Lai F, Li E, Tam L (2007) Intrarenal cytokine gene expression in lupus nephritis. Ann Rheum Dis 66: 886-892.
5. Chun H, Chung J, Kim H (2007) Cytokine Il-6 and Il-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol 27: 461-467.
6. Esposito P (2009) Interleukin-6 release from peripheral mononuclear cells is associated to disease activity and treatment response in patients with lupus nephritis. Lupus 18: 1329-1330.
7. Fiehn C, Hajjar Y, Mueller K, Waldherr R and Ho AA, K (2003) Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Annals Rheumatic Dis 62: 435-439.
8. HochbergM(1997) Updating the American College of Rheumatology Criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40: 1725.
9. Illei G, Tackey E, Lapteva L, Lipsky P (2004) Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum 50: 2048-2065.
10. Masutani K, Akahoshi M, Tsuruya K (2001) Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum 44: 2097-2106.
11. Morimoto S, Tokano Y, Nakano S, Watanabe T (2009) Chemoattractant mechanism of Th1 cells in class III and IV lupus nephritis. Autoimmunity 42(2): 143-149.
12. Oates J, Varghese S, Bland A (2005) Prediction of urinary protein markers in lupus nephritis. Kidney Int 68: 2588-2592.
13. Reyes-Thomas J, Blanco I, Putterman C (2011) Urinary biomarkers in lupus nephritis. Clinic Rev Allerg Immunol 40: 138-150.
14. Rovin B, Song H, Birmingham D (2005) Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 16: 467-473.
15. Schwartz N, Michaelson J, Putterman C (2007) Lipocalin-2, TWEAK, and other cytokines as urinary biomarkers for lupus nephritis. Ann NZ Acad Sci 1109: 265-274.
16. Schwartz N, Su L, Burkly L (2006) Urinary TWEAK and the activity of lupus nephritis. J Autoimmunity. J Autoimmunity 27: 242-250.
17. Sinico R, Radice A, Ikehata M, Giammarresi G, Corace C, Arrigo G (2005) Anti-C1q antibodies in lupus nephritis: prevalence and clinical significance. Ann N Y Acad Sci 1050: 193-200.
18. Weening J, D'Agati V, Schwartz M (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65: 521-530.
19. Wu T, Xie C, Wang H (2007) Elevated urinary VCAM-1, P-selectin, soluble TNF-receptor-1 and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J Immunol 179: 7166-7175.